Asclera, an injection sclerotherapy medicine from Merz Aesthetics, is now being shipped to physicians' offices throughout the U.S. Asclera was approved by the Food and Drug Administration (FDA) on March 30 of this year after being available in Europe for years, and is now available to treat spider veins in America.
Asclera treats uncomplicated spider and reticular veins in the lower extremities, and has not been studied in larger varicose veins. Once injected, Asclera damages the cell lining of blood vessels, causing them to close and eventually disappear.
According to a study published in the June issue of Phlebology, leading experts conclude that Asclera (polidocanol) is a highly effective sclerotherapy treatment. The authors found that Asclera demonstrated significant efficacy over other treatment options, and patients reported better satisfaction with polidocanol than with other treatment options. The study also showed that treatment with Asclera was safe and generally well tolerated.
"The arrival of Asclera has been highly anticipated among physicians, with very positive initial reactions and the number of pre-orders exceeding our expectations," said Dennis Condon, President of BioForm Medical, Inc., a Merz Aesthetics company. "We are proud to finally deliver the next level of cosmetic procedure performance that physicians and patients demand."